SMYD3 and neoplasm: We next assessed whether the decreased tumor growth and metastatic burden caused by repression of SMYD3 in the PC-3 xenografts could be rescued by expressing wild-type SMYD3 or the catalytically inactive F183A mutant (Fig. 3G).